Centocor Microarray Study of Patients

This study has been completed.
Sponsor:
Collaborator:
Centocor, Inc.
Information provided by (Responsible Party):
Christopher Ritchlin, University of Rochester
ClinicalTrials.gov Identifier:
NCT00462072
First received: April 17, 2007
Last updated: December 9, 2011
Last verified: December 2011
  Purpose

Specific Aim 1. To determine the transcriptome of peripheral blood mononuclear cells isolated monocytes and target tissues in IMIDs.

Specific Aim 2. To analyze the change in gene expression profiles in patients with Crohn's disease, psoriatic and rheumatoid arthritis before and after infliximab therapy.


Condition Intervention Phase
Rheumatoid Arthritis
Psoriatic Arthritis
Psoriasis
Crohn's Disease
Drug: Infliximab
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Microarray Analysis of Peripheral Blood and Tissues of Patients With Immune Mediated Inflammatory Diseases

Resource links provided by NLM:


Further study details as provided by University of Rochester:

Primary Outcome Measures:
  • Baseline (Wk 0) Disease Activity Score (DAS28) [ Time Frame: Baseline (Wk 0) ] [ Designated as safety issue: No ]
    The DAS28 for RA and PsA subjects is an outcome measure used in determining the severity of an individual's disease. This score is used to assess disease activity and to make and monitor treatment decisions. The baseline DAS28 is an average of the study populations baseline disease activity score prior to the administration of Infliximab (remicade). A DAS28 score of higher than 5.1 is indicative of high disease activity, whereas a DAS28 below 3.2 indicates low disease activity. A subject is considered to be in remission if they have a DAS28 lower than 2.6.

  • Week 10 Disease Activity Score (DAS28) [ Time Frame: Week 10 ] [ Designated as safety issue: No ]
    The DAS28 for RA and PsA subjects is an outcome measure used in determining the severity of an individual's disease. This score is used to assess disease activity and to make and monitor treatment decisions. The week 10 DAS28 is an average of the study population's week 10 disease activity score after taking infliximab (remicade) for 10 weeks. A DAS28 score of higher than 5.1 is indicative of high disease activity, whereas a DAS28 below 3.2 indicates low disease activity. A subject is considered to be in remission if they have a DAS28 lower than 2.6.

  • Disease Activity Score (DAS28) Delta [ Time Frame: Week 10 ] [ Designated as safety issue: No ]
    The DAS28 Delta for RA and PsA subjects is measure used to determine the change in the severity of an individual's disease with positive delta indicating an improvement in the severity of subject's disease and a negative delta indicating a worsening of a subject's disease. The delta score is used to monitor treatment. The week 10 DAS28 Delta is determined by calculating the average change between the wk 0 and wk 10 DAS28.

  • Baseline (Wk 0) Psoriasis Area and Severity Index (PASI) [ Time Frame: Baseline (Wk 0) ] [ Designated as safety issue: No ]
    A PASI score for Ps subjects is an outcome measure used in determining the severity of an individual's disease. This score is used to assess disease activity and to make and monitor treatment decisions. The baseline PASI is an average of the study populations baseline disease activity score prior to the administration of infliximab (remicade). While higher PASI scores indicate more severe psoriasis, it is difficult for subjects or doctors to describe the clinical severity for any specific PASI number.

  • Baseline (Wk 10) Psoriasis Area and Severity Index (PASI) [ Time Frame: Week 10 ] [ Designated as safety issue: No ]
    A PASI score for Ps subjects is an outcome measure used in determining the severity of an individual's disease. This score is used to assess disease activity and to make and monitor treatment decisions. The week 10 PASI is an average of the study population's week 10 disease activity score after taking infliximab (remicade) for 10 weeks.

  • Psoriasis Area and Severity Index (PASI) Delta [ Time Frame: Week 10 ] [ Designated as safety issue: No ]
    The PASI Delta for Ps subjects is a measure used to determine the change in the severity of an individual's disease with a positive delta indicating an improvement in the severity of subject's disease and a negative delta indicating a worsening of a subject's disease. The delta score is used to monitor treatment. The week 10 PASI Delta is determined by calculating the average change between the wk 0 and wk 10 PASI.


Enrollment: 31
Study Start Date: March 2007
Study Completion Date: August 2010
Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Infliximab
    Subjects will be on a stable dose of methotrexate 12.5 to 20 mg per week and will be started on infliximab 5 mg/kg.
Detailed Description:

Our hypothesis is that hematopoietic stem cells are very sensitive to elevated levels of TNFa, which potentiates their differentiation into myeloid effector cells. During their migration from the bone marrow to the end organ, these cells express a unique set of genes that function to prime these cells to respond to critical differentiation signals. Elucidation of this transcriptome through microarray analysis will provide insight into novel drug targets and a formal understanding of the biochemical and molecular genetic events linking IMIDs. To test our hypothesis, will determine the transcriptome in peripheral blood mononuclear cells and isolated monocytes from 20 normal healthy donors, 10 patients with psoriatic arthritis, 10 patients with psoriasis, 10 patients with Crohn's disease and 10 patients with rheumatoid arthritis. The transcriptome will also be examined in inflamed intestinal tissue from patients with Crohn's disease, psoriatic skin and synovial tissue from patients with rheumatoid and psoriatic arthritis.

  Eligibility

Ages Eligible for Study:   12 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Rheumatoid Arthritis

  • 18 years of age or older
  • 3 years duration of disease or less
  • Must meet ACR criteria
  • 3 tender or swollen joints
  • Positive RF or anti-CCP antibodies or evidence of erosions on plain radiographs
  • CRP > 1.5
  • Non-responder to methotrexate, but on a stable dose of 12.5 to 20 mg/week
  • Only subjects scheduled to receive infliximab as part of their care are eligible to participate.

Crohn's disease

  • 12 years of age or older
  • Clinical and endoscopic confirmation of disease
  • CDAI > 220 or evidence of intestinal inflammation on endoscopy
  • Documented failure to conventional therapy.
  • Only subjects scheduled to receive infliximab as part of their care are eligible to participate.

Psoriatic arthritis

  • 18 years of age or older
  • Must meet CASPAR® criteria for diagnosis
  • RF and anti-CCP negative
  • 3 tender or swollen joints
  • Non-responder to methotrexate, but on a stable dose of 12.5 to 20 mg/week
  • Only subjects scheduled to receive infliximab as part of their care are eligible to participate.

Psoriasis

  • 18 years of age or older
  • Total BSA > 5%

Exclusion Criteria:

  • Candidates for whom the procedures would be medically contraindicated would be excluded.
  • Patients with any active infections (viral or bacterial) will not be considered for inclusion into the trial.
  • Patients with history of chronic infection such as hepatitis, pneumonia or chronic pyelonephritis; those with current signs or symptoms of severe or progressive or uncontrolled renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, cardiac, neurologic or cerebral disease including demyelinating disease such as multiple sclerosis.
  • Those with history of lymphoproliferative disease such as lymphoma or signs suggestive of lymphoproliferative disease, such as lymphadenopathy of unusual size or location (such as nodes in the posterior triangle of the neck, supraclavicular, epitrochlear, or periaortic areas), or splenomegaly will be excluded.
  • Patients with concomitant diagnosis of CHF, including medically controlled asymptomatic patients will not be eligible to participate.
  • Any current known malignancy or history of malignancy in the last 10 years will be excluded. History of basal cell carcinoma is not excluded.
  • Those with known bacterial, tuberculosis or opportunistic infections including but not limited to evidence of active cytomegalovirus , active Pneumocystis carinii, aspergillosis, or atypical mycobacterium infection within the previous 6 months will be ineligible.
  • Those with known infection with Human immunodeficiency virus (HIV) or known active hepatitis B or C (including associated active hepatitis) will be excluded.
  • Known substance abuse (drug or alcohol) within the previous 3 years.
  • Patients who have previously taken anti-TNF therapy are not eligible.
  • Patients who have been treated with DMARDS, biologic or investigational agents must wash out for at least 6 weeks prior to enrollment with the exception of those on methotrexate, who must be on a stable dose at least 2 weeks prior to start of study.
  • Have a history of latent or active granulomatous infection, including TB, histoplasmosis, or coccidioidomycosis, prior to screening.
  • Have had a Bacille Calmette-Guerin (BCG) vaccination within 12 months of screening.
  • Have a chest radiograph within 3 months prior to the first administration of study agent that shows an abnormality suggestive of a malignancy or current active infection, including TB.
  • Have had a nontuberculous mycobacterial infection or opportunistic infection (eg, cytomegalovirus, Pneumocystis carinii, aspergillosis) within 6 months prior to screening.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00462072

Locations
United States, New York
University of Rochester
Rochester, New York, United States, 14642
Sponsors and Collaborators
University of Rochester
Centocor, Inc.
Investigators
Principal Investigator: Christopher Ritchlin, MD University of Rochester
  More Information

No publications provided

Responsible Party: Christopher Ritchlin, M.D., M.P.H.; Professor of Medicine Allergy, Immunology & Rheumatology Division, University of Rochester
ClinicalTrials.gov Identifier: NCT00462072     History of Changes
Other Study ID Numbers: MA-01
Study First Received: April 17, 2007
Results First Received: August 2, 2011
Last Updated: December 9, 2011
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Arthritis
Arthritis, Psoriatic
Arthritis, Rheumatoid
Crohn Disease
Psoriasis
Joint Diseases
Musculoskeletal Diseases
Spondylarthropathies
Spondylarthritis
Spondylitis
Spinal Diseases
Bone Diseases
Skin Diseases, Papulosquamous
Skin Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Inflammatory Bowel Diseases
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases
Infliximab
Dermatologic Agents
Therapeutic Uses
Pharmacologic Actions
Gastrointestinal Agents
Antirheumatic Agents
Anti-Inflammatory Agents

ClinicalTrials.gov processed this record on April 23, 2014